Drugs / TANZISERTIB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01466725 | Nov 2011 → Jul 2012 | discoid lupus erythematosus | Celgene Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT01203943 | Jan 2011 → Jan 2012 | idiopathic pulmonary fibrosis, pulmonary fibrosis | Celgene Corporation | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TANZISERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL1950289 ↗ |
| Known as | CC-930 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01203943 ↗ |
| Known as | JNK 930 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1950289 ↗ |
| Action | Inhibit | “c-Jun N-terminal kinase 1 inhibitor” CHEMBL1950289 ↗2“c-Jun N-terminal kinase 3 inhibitor” CHEMBL1950289 ↗ “c-Jun N-terminal kinase 2 inhibitor” CHEMBL1950289 ↗ |
| Modality | Small molecule | — CHEMBL1950289 ↗ |
| Route | Oral | “50 mg PO daily up to 56 weeks beginning on Day 1” NCT01203943 ↗ |
| Target | MAPK10 | “c-Jun N-terminal kinase 3 inhibitor” CHEMBL1950289 ↗ |
| Target | MAPK8 | “c-Jun N-terminal kinase 1 inhibitor” CHEMBL1950289 ↗ |
| Target | MAPK9 | “c-Jun N-terminal kinase 2 inhibitor” CHEMBL1950289 ↗ |